CYP3A4 and Adrenal insufficiency: For nearly a decade, this medication was the only orally available antifungal agent (Maertens, 2004), but it has been conclusively linked to potentially severe safety issues (hepatoxicity, adrenal insufficiency, and Cytochrome P450 3A4 (Cyp3A4) mediated drug/drug interaction).